"There will be a huge value
placed on the company by its shareholders on predictability. This may be
especially tough for a company like Diplomat…given the pricing pressures from
plan sponsors, payers and pharmaceutical manufacturers that may adversely affect
profitability."
— Stephen Cichy, founder and managing director at Monarch
Specialty Group, LLC, talked with AIS's RADAR
on Specialty Pharmacy about Diplomat Pharmacy's acquisition by
UnitedHealth, and why the company's decision to go public may have fueled its
financial difficulties.
No comments:
Post a Comment